Recommendation of the President – Reagila (cariprazine)
On 5 December 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 140/2024 on the appraisal of the drug Reagila (cariprazine) for the indication: treatment of adult patients with schizophrenia after ineffectiveness or in case of contraindications to therapy with other second-generation antipsychotic drugs